Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rilmenidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH known ✓ | Q9Y2I1 | 6/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 12/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 12/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 11/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rilmenidine SCHEMBL15516636 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CNISCHADRA1A | |
| SCHEMBL6368709 | 0.91 | ADRA2A (0.83) | ADRA2AADRA2BADRA2CNISCHADRA1A | |
| Rilmenidine SCHEMBL1231349 | 0.90 | ADRA2A (0.81) | ADRA2AADRA2BADRA2CNISCHADRA1A | |
| Rilmenidine SCHEMBL6373730 | 0.86 | ADRA2A (0.73) | ADRA2AADRA2BADRA2CNISCHADRA1A | |
| Rilmenidine SCHEMBL30892124 | 0.86 | CYP3A4 (1.00) | ADRA2AADRA2BADRA2CNISCHADRA1A | |
| SCHEMBL11639239 | 0.81 | ADRA2A (0.68) | ADRA2AADRA2BADRA2CNISCHADRA1A | |
| SCHEMBL11668019 | 0.78 | ADRA2A (0.64) | ADRA2AADRA2BADRA2CNISCHADRA1A | |
| SCHEMBL11140750 | 0.77 | ADRA2A (0.62) | ADRA2AADRA2BADRA2CNISCHADRA1A | |
| SCHEMBL13616145 | 0.77 | ADRA2A (0.62) | ADRA2AADRA2BADRA2CNISCHADRA1A | |
| SCHEMBL11638113 | 0.77 | ADRA2A (0.62) | ADRA2AADRA2BADRA2CNISCHADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2957 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122047286-A | Large-model-based intelligent agent construction framework and behavior simulation method and device | 北京华如科技股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| EP-4101448-B1 | COMPOSITION COMPRISING RILMENIDINE COMPOUND AS ACTIVE INGREDIENT FOR TREATMENT OF FRAGILE X SYNDROME OR RELATED DEVELOPMENTAL DISABILITY | NEUROVENTI (KR) | 2026-04-22 | — | — | EP | claimed |
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | claimed |
| US-12396983-B2 | Composition comprising rilmenidine compound as active ingredient for treatment of fragile X syndrome or related developmental disability | NEUROVENTI (KR) | 2025-08-26 | — | — | US | claimed |
| US-20250228817-A1 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | AMAZENTIS SA (CH) | 2025-07-17 | — | — | US | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | MINDSTATE DESIGN LABS INC (US) | 2025-06-05 | — | — | US | claimed |
| WO-2025080559-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ENALARE THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | claimed |
| US-20250114370-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ENALARE THERAPEUTICS INC (US) | 2025-04-10 | — | — | US | claimed |
| WO-2025067458-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITION AND USE THEREOF | 苏州普乐康医药科技有限公司 | 2025-04-03 | — | — | WO | claimed |
| WO-2000021509-A2 | METHODS OF TREATMENT | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2000-04-20 | — | — | WO | claimed |
| US-5605911-A | NEUROTOXIC SIDE EFFECT INHIBITION | WASHINGTON UNIVERSITY (US) | 1997-02-25 | — | — | US | claimed |
| EP-0719139-A1 | USE OF CENTRALLY ACTIVE ALPHAAGONISTS FOR INHIBING POSTRAUMATIC METABOLIC STRESS | Dr. Karl Thomae GmbH (DE) | 1996-07-03 | — | — | EP | claimed |
| US-5459133-A | Methods and products for treating presbyopia | TELOR OPHTHALMIC PHARMACEUTICALS, INC. (US) | 1995-10-17 | — | — | US | claimed |
| EP-0643576-A1 | ALPHA-2-ADRENERGIC AGONISTS FOR TREATING PRESBYOPIA | TELOR OPHTHALMIC PHARMACEUTICALS, INC. (US) | 1995-03-22 | — | — | EP | claimed |
| WO-1995003798-A2 | USE OF CENTRALLY EFFECTIVE α-2 AGONISTS FOR INHIBITING POSTAGGRESSION METABOLISM | BOEHRINGER INGELHEIM INT (DE) | 1995-02-09 | — | — | WO | claimed |
| WO-1993025199-A1 | ALPHA-2-ADRENERGIC AGONISTS FOR TREATING PRESBYOPIA | TELOR OPHTHALMIC PHARMACEUTICALS, INC. (US) | 1993-12-23 | — | — | WO | claimed |
| EP-0510052-A1 | MEDICAMENT FOR TREATMENT OF HEART FAILURE | HEDNER, Thomas (SE) | 1992-10-28 | — | — | EP | claimed |
| WO-1991009627-A1 | MEDICAMENT FOR TREATMENT OF HEART FAILURE | HEDNER THOMAS (SE) | 1991-07-11 | — | — | WO | claimed |
| US-4102890-A | HYPNOTIC, ANALGESIC, HYPOTENSIVE, CARDIOVASCULAR DEPRESSANTS, NEURO-MODULATORS | SCIENCE-UNION ET CIE, SOCIETE FRANCAISE DE RECHERCHE MEDICALE (FR) | 1978-07-25 | — | — | US | claimed |